ASCO 2016: The risk of infection for CLL patients receiving idelalisib
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX discusses the safety of idelalisib for chronic lymphocytic leukemia (CLL). Dr Wierda outlines the risk of in...
Author: VJHemOnc
Added: 06/15/2016
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Texas University